| Drug Name |
Carboprost |
| Drug ID |
BADD_D00365 |
| Description |
A nonsteroidal abortifacient agent that is effective in both the first and second trimesters of pregnancy. |
| Indications and Usage |
For aborting pregnancy between the 13th and 20th weeks of gestation as calculated from the first day of the last normal menstrual period and in the following conditions related to second trimester abortion: 1. Failure of expulsion of the fetus during the course of treatment by another method; 2. Premature rupture of membranes in intrauterine methods with loss of drug and insufficient or absent uterine activity; 3. Requirement of a repeat intrauterine instillation of drug for expulsion of the fetus; 4. Inadvertent or spontaneous rupture of membranes in the presence of a previable fetus and absence of adequate activity for expulsion. Also for the treatment of postpartum hemorrhage due to uterine atony which has not responded to conventional methods of management. |
| Marketing Status |
Not Available |
| ATC Code |
G02AD04 |
| DrugBank ID |
DB00429
|
| KEGG ID |
D02343
|
| MeSH ID |
D002260
|
| PubChem ID |
5281075
|
| TTD Drug ID |
Not Available
|
| NDC Product Code |
43598-917; 0009-0856; 54893-0023; 68245-0016; 70121-1680; 82231-103; 43598-698; 69784-240; 43598-919 |
| Synonyms |
Carboprost | 15-Methylprostaglandin F2alpha | 15 Methylprostaglandin F2alpha | 15(S)-15-Methyl PGF2alpha |
